

9–12 December 2025
Adelaide Convention Centre
South Australia

www.ascept-hypertensionau.com.au

Tuesday 9 December 2025


08:30 – 18:00	Registration desk open			Foyer E
Room	E1	E2	E3	Hall C Lower Section
09:00 – 11:00	WORKSHOP 1 Binding affinity prediction with deep learning: practical workshop using PSICHIC model	WORKSHOP 2 ANZ Prescribing Skills Assessment 100 Question Challenge		WORKSHOP 3 2025 Australian Guideline for the Diagnosis and Management of Hypertension
Chair	Emma van der Westhuizen, St Vincent's Institute	A/Prof Kellie Charles, The University of Sydney and Dr Paul Chin, University of Otago		Prof Gerry Jennings AO, Heart Foundation
	Facilitators: Dr Anh Thi Ngoc Nguyen, Monash University Huan Yee Koh, Monash University	Introduction to generative AI MCQ agents for drafting ANZ PSA exam questions A/Prof Matt Doogue, University of Otago & Health New Zealand		Facilitators: Prof Markus Schlaich, Hypertension Centre, Royal Perth Hospital, University of Western Australia Dr Dannii Dougherty, Heart Foundation Prof Garry Jennings AO, Heart Foundation Prof Ross Tsuyuki, University of Alberta
11:00-11:30	Comfort break			
11:30 – 13:30	WORKSHOP 4 Assessing student understanding and application of the core concepts of pharmacology	WORKSHOP 5 From pipettes to policy: a world of career choices (combined ASCEPT& HA ECR committee)	WORKSHOP 6 What's the "T"	Hypertension Taskforce Summit (11.15-16.45)
Chair	Prof Paul White, Monash University	Hericka Figueiredo Galvao, La Trobe University, Alemayehu Jufar, The Florey Institute of Neuroscience and Mental Health, Aisling McEvoy, Monash University and Mariah Stavrou, UNSW Sydney	Dr Felicity Grzemeski, Novotech-cro and Tarah Hogen, SLR Consulting Australia Pty Ltd	Markus Schlaich, Royal Perth Hospital - University of Western Australia
	Facilitators: Prof Paul White, Monash University Dr Suong Ngo, The University of Adelaide Dr Tori Llewelyn, Flinders University A/Prof Tina Hinton, The University of Sydney A/Prof Betty Exintaris, Monash University A/Prof Lynette Fernandes, University of Western Australia Dr Marina Junqueira Santiago, Macquarie University Dr Anna-Marie Babey, University of New England Dr Gregg Maynard, Charles Sturt University Dr Nilushi Karunaratne, Monash University	Panel: Dr Wubshet Tesfaye, University of Queensland Dr Aili Langford, The University of Sydney Dr George Tan, Monash University Dr Quynh Dinh, RMIT University Dr Rikeish R Muralitharan, Monash University, Victorian Heart Institute Dr Audrey Adj, Victor Chang Cardiac Research Institute and St Vincent's Centre for Applied Medical Research	The interdisciplinary life of an academic toxicologist A/Prof Paul Wright, RMIT University The interdisciplinary life of a consultant toxicologist and health risk assessor Tarah Hagen, SLR Consulting Australia Pty Ltd Careers in nonclinical toxicology in a Contract Research Organisation Lynne Clapham, Agilix Biolabs Role of a Toxicologist in Clinical Trial Initiation and Progression Dr Sharleen Menezes, Novotech Role of Clinical Toxicologist in the medical setting Prof Nick Buckley, The University of Sydney Toxicology roles in Government Effi Liden, Australian Pesticides & Veterinary Medicines Authority The role of the toxicologist in the Therapeutic Goods Administration (TGA) and regulatory science Adj A/Prof Brian Priestly, Monash University	
13:30-14:00	Education Forum AGM	Student Forum AGM		
13:30-14:00	Comfort break			
14:00 – 16:00	WORKSHOP 7 Evaluation of Individual Patient Applications (IPAs) for unfunded Medications	WORKSHOP 8 Crash-course on quantification of allosteric and biased signalling at G protein-coupled receptors	WORKSHOP 9 Visibility in STEM and Medical Practice/Research/Higher Education: Empowering Diverse Voices	
Chair	Nicholas Farinola, Central Adelaide Local Health Network and Tilenka Thynne, Flinders Medical Centre	Dr Celine Valant, Monash University	Audrey Adj, Victor Chang Cardiac Research Institute and St Vincent's Centre for Applied Medical Research and Brendan Wilkins, UNSW Sydney	
	Facilitators: A/Prof Matt Doogue, University of Otago & Health New Zealand Dr Sally Fotheringham, Royal Prince Alfred Hospital Dr David Liew, Austin Health Dr Angela Molga, Central Adelaide Local Health Network	Facilitators: Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences Dr Celine Valant, Monash University Dr Vi Pham, Monash Institute of Pharmaceutical Science Jasmin Li, Monash University Dr Arisbel Batista Gondin, Monash University	Presenters: A/Prof Courtney Ryder, Flinders University Conjoint A/Prof Darren Roberts, Sydney Local Health District; Sydney Children's Hospital Network	

	An introduction to D/MTCs, IPUs and some of the challenges faced Prof Sarah Hilmer, Royal North Shore Hospital & The University of Sydney		Panel: Dr Norma Bulamu, Flinders University Dr Maria Alejandra Pinero de Plaza, Flinders University Alex Burke, University of Sydney Dr Rikeish Muralitharan, Monash University Dr Marina Junqueira Santiago, Macquarie University Dr Danial Saifuddin, The University of Queensland	
	Core skill sets for evaluation of medicines Prof Madlen Gazarian, UNSW Sydney			
	IPAs in Oncology Dr Imogen Walpole, Austin Health			
	Influence of Pharma on IPU applications Joel Iedema, Metro South Hospital and Health service			
16:00-16:30	Clinical Pharmacology AGM	Drug Discovery AGM	Urogenital & Gastrointestinal AGM	
16:30-17:00	New ASCEPT members networking			Foyer E
17:00 – 17:20	Meeting opening		Sponsored by Bb Bellberry Limited supporting research and ethics	Hall C Lower Section
17:20-18:15	100. Opening keynote address I Repurposing the repurposed: the evolving journey of methotrexate Prof Arduino Mangoni, Flinders University			
Chair	Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney			
18:15-18:30	ASCEPT Fellowship awards presentations			
Chair	Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney			
18:30 – 20:00	Welcome reception		Sponsored by Bb Bellberry Limited supporting research and ethics	

Medtronic

ACC/AHA hypertension guidelines are here!
Renal denervation now recommended.¹

The renal denervation blood pressure procedure – which uses the **Symplcity Spyril™ renal denervation system** – complements existing hypertension treatments to help provide significant and sustained blood pressure reductions for patients with uncontrolled hypertension.²⁻⁵ **Sustained reductions: 17mmHg mean reduction** in office SBP in real-world registry at 3 years (n = 1137) ⁴



1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Published online August 14, 2025.
2. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. *Lancet*. April 9,2022;399(10234):1401-1410.
3. Mahfoud F, Schlaich M, Schmieder RE, et al. Long-term outcomes in ESC guideline-recommended patients for RDN from Global SYMPPLICITY Registry DEFINE. Presented at: EuroPCR; May 20-23, 2025; Paris, France.
4. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, shamcontrolled trial. *Lancet*. May 2, 2020;395(10234):1444-1451.
5. Kandzari D, Townsend R, Kario K, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. *J Am Coll Cardiol*. November 7, 2023;82(19):1809-1823.

Medtronic Australasia Pty Ltd, Level 8, 11 Khartoum Road, Macquarie Park, NSW 2113, Australia, Tel: +61 2 9857 9000, Fax: +61 2 9889 5167, Toll Free: 1800 668 670, medtronic.com.au | Medtronic New Zealand Ltd, Level 3 - Building 5, Central, Park Corporate Centre, 666 Great South Road, Penrose, Auckland 1051, New Zealand, Fax: +64 9 918 3742, Toll Free: 0800 377 807 | ©2025 Medtronic. All rights reserved. 20358926 | AU-NA-2500036

07:00 – 08:00	Morning run/walk (free activity) Meeting point: Adelaide Rowing Club			
07:30 – 18:00	Registration desk open			Foyer E
08:00 – 08:50	200. ASCEPT Keynote presentation: BPS lecture I Role of Endothelial Receptors in the Hypertension Induced by VEGFR-2 Inhibitors Prof Jeanette Woolard, University of Nottingham			Hall C Lower Section
Chair	Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney			
CONCURRENT SESSION 1				
Room	E1	E2	E3	Hall C Lower Section
09:00 – 10:30	Oral presentations 1: Education & Gillian Shenfield Early Educator Award	Oral presentations 2: Pharmacoepidemiology	Oral presentations 3: Clinical pharmacology Sponsored by 	Oral presentations 4: Cognition and brain injury
Chair:	Assist/Prof Iris Lim, Bond University and Dr George Tan, Monash University Kellie Charles (GS award)	Dr Emily Reeve, Monash University and Harry Le, The University of Sydney	Kerry Watts, Advanced Therapeutics NSW Ministry of Health and Dr Chris Cameron, Wellington Hospital	Dr Adriana Knezic, Monash University and Prof Gavin Lambert, Swinburne University of Technology
09:00-09:15	201. Rethinking Assessment: OSPEs Provide Authentic Alternatives in the Generative AI Era Dr Nilushi Karunaratne, Monash University	207. Prescription sequence symmetry analysis of glucagon-like peptide-1 receptor agonist and neuropsychiatric conditions Dr George Tan, Monash University	213. Pharmacokinetics, and efficacy/safety, of thioguanine suppositories in patients with refractory proctitis Prof Murray Barclay, Christchurch Hospital	219. Safety and efficacy of RDN post-stroke: results from the Global SYMPLICITY Registry Gianni Sesa-ashton, Baker Heart and Diabetes Institute
09:15-09:30	202. Are interactive oral interview assessments only useful as a secure AI assessment? A/Prof Kellie Charles, The University of Sydney	208. Drug Burden Index–guided stewardship intervention to deprescribe in Older Acute Inpatients Dr Kenji Fujita, Kolling Institute	214. Is one-dose-for-all suitable for low dose colchicine in patients with gout? A/Prof Daniel Wright, The University of Sydney	220. Pre-existing Heart Failure Exacerbates Neuroinflammation After Cardiopulmonary Bypass Dr Lindsea Booth, Florey Institute
09:30-09:45	203. How does generative AI impact student motivation and academic self-efficacy? A/Prof Tina Hinton, The University of Sydney	209. Clusters of psychotropic and health service use in people with dementia Edward Chun Yin Lau, The University of Sydney	215. Is it time to replace the ‘prescription’ with the medication management plan? A/Prof Matt Doogue, University of Otago & Health New Zealand	221. Cardiovascular mechanobiomarkers relate to poorer cognition in older Australians. The Mind-Your-Heart Study Dr Louise Goodall, Garvan Institute
09:45-10:00	204. Sustainable organ bath pharmacology experiments for continued experiential learning in science Dr Brent McParland, The University of Sydney	210. Mapping multimorbidity clusters in older Australians using linked administrative health data Dr Edwin Tan, The University of Sydney	216. Therapeutic benefits of megadose sodium ascorbate for blood pressure management in sepsis Maya Bishop, The University of Melbourne	222. Associations of blood pressure parameters with cognitive decline and dementia: umbrella review Dr Sultana Shajahan, The George Institute for Global Health
10:00-10:15	205. Health professional co-teaching teams enhance clinical pharmacology learning and teaching in optometry Dr Tori Llewelyn, Flinders University	211. Age-stratified trends in Australian prescribing of controlled ovarian hyperstimulation medications between 2016-2024 Toni Michael, The University of Sydney	217. Predictors of non-cardiovascular readmissions in multimorbid adults with heart failure Dr Joshua Inglis, Flinders Medical Centre	223. Association between Arterial Stiffness and Cognitive Decline in an Older Chinese Population Dr Audrey Adj, Victor Chang Cardiac Research Institute and St Vincent's Centre for Applied Medical Research
10:15-10:30	206. Strategies for effective teamwork in the pharmacology practical class (Gillian Shenfield Early Educator Award) Dr Makhala Khammy, The University of Melbourne	212. Incidence and profiles of poisonings in older people with dementia in Sweden Ilsa Wojt, The University of Sydney	218. Co-design of medication management resources for people with dementia in the community Xenia Nastatos, The University of Sydney	224. Seizure-induced cardiovascular dysregulation: a clinically relevant sheep model for SUDEP therapeutics development Dr Ruslan Pustovit, Florey Institute of Neuroscience and Mental Health
10:30 – 11:00	Morning tea with exhibitors			Foyer E
10:30-11:00	Poster presentations Cardiovascular, Innovation & Industry, Clinical pharmacology, Drug discovery, Pharmacoepidemiology, Pharmacogenomics, Comorbidities, Complications of hypertension, Mechanisms of hypertension, Risk factors			
CONCURRENT SESSION 2				
Room	E1	E2	E3	Hall C Lower Section
11:00 – 13:00	Symposium 1: Toxicology Today and Tomorrow: Global Trends in Focus, Techniques and Regulation	Symposium 2: Genetic diversity in drugs targets	Symposium 3: Cardiorespiratory immunopharmacology: state-of-the-art models and novel drugs	Symposium 4 (HA): Advances in treatment for paediatric hypertension and obesity
Chair	Dr Ian Musgrave, University of Adelaide and Tayler Catherine Kent, Murdoch University	Dr Pramod Nair, Flinders University and Dr Eryn Werry, The University of Sydney	A/Prof Graham Mackay, University of Melbourne	A/Prof Jonathan Mynard, Murdoch Children’s Research Institute and Adj A/Prof Rae-Chi Huang, Edith Cowan University and Perth Children’s Hospital
11:00-11:30	225. Climatoxicology: ACTRA warns that climate change is impacting the toxicology and risk assessment of chemical exposures A/Prof Paul Wright, RMIT University	229. New therapeutics from neo-epitope sequences for myelofibrosis A/Prof Daniel Thomas, University of Adelaide, SAHMRI	233. Environmental Exposures on the Cardiorespiratory system: New Models, Drug Targets and Treatment Approaches Dr Richard Kim, University of Technology Sydney	237. Emerging therapies for treatment resistant hypertension Prof Markus Schlaich, Dobney Hypertension Centre, Royal Perth Hospital, University of Western Australia
11:30-12:00	226. Toxicology challenges of emerging pharmaceutical modalities Dr Sharleen Menezes, Novotech	230. Development of radiotracers for TSPO polymorphisms Grace Cumbers, The University of Sydney	234. Advancing Strategies in Cardiopulmonary Disease: Pioneering Pathways to Therapeutic Innovation Dr Chengxue Helena Qin, Monash University	238. New Australian Guideline for Children and Adolescents - when, why and how to manage BP in children Dr Nicholas Larkins, Perth Children’s Hospital
12:00-12:30	227. Thought for food: assessing agricultural risks from PFAS in the current regulatory environment Tarah Hagen, SLR Consulting Australia Pty Ltd	231. Patients carrying epilepsy-causing variants in GABAA receptors require treatments based on a precision medicine approach Prof Mary Chebib, The University of Sydney	235. Thinking Outside the Box: Immune-Modifying Methods to Reduce Lung Infections on the Cardiovascular System Dr Madison Coward-Smith, University of Technology Sydney	239. DASH diet resource to support lifestyle intervention for paediatric hypertension Arielle Hyland, Perth Children’s Hospital
12:30-13:00	228. Non-animal models: Current status for toxicology and specific challenges including virtual control groups, in silico modelling, AI predictive tools, organ on a chip/organoids Dr Slade Matthews, The University of Sydney and Lynne Clapham, Agilix Biolabs	232. Novel GRM1 mutations in juvenile ataxia Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences	236. Endogenous TGF-β immune suppression in chronic inflammatory lung disease Dr Belinda Thomas, Monash University	240. Emerging treatments for obesity in children, and impact on blood pressure Dr Danielle Longmore, Royal Children’s Hospital

13:00 – 14:00	Lunch with exhibitors			Sponsored by 	Foyer E
13:00 – 14:00	Poster presentations Cardiovascular, Innovation & Industry, Clinical pharmacology, Drug discovery, Pharmacoepidemiology, Pharmacogenomics, Comorbidities, Complications of hypertension, Mechanisms of hypertension, Risk factors				
13:15 -14:00	Hypertension Australia Board Meeting				
13:00-14:00	LUNCH WORKSHOP: Leveraging Novel Methodologies to Address Key Challenges in Drug Discovery and Development Dr Kenneth Brouwer, BioIVT				E1
CONCURRENT SESSION 3					
Room	E1	E2	E3	Hall C Lower Section	
14:00 – 15:30	Oral presentations 5: Toxicology / Innovation and industry	Oral presentations 6: Drug discovery / Pharmacogenomics	Oral presentations 7: Cardiovascular / Respiratory and inflammation	Oral presentations 8: New therapies and management of hypertension	
Chair	Dr Susan Britza, The University of Adelaide and Dr Brendan Wilkins, UNSW Sydney	Toni Michael, The University of Sydney and Prof Kevin Pflieger, The University of Western Australia	Dr Paris Papagianis, Monash University and David Wong Zhang, La Trobe University	Dr Niamh Chapman, The University of Sydney and Prof Mark Nelson, University of Tasmania	
14:00-14:15	241. Active Learning with Thompson Sampling for hERG Risk Modelling in Drug Development Dr Slade Matthews, The University of Sydney	247. Bi-specific diabodies targeting β -amyloid to microglial phagocytic proteins for treating neurodegenerative diseases Dr Emma Van Der Westhuizen, St Vincent's Institute of Medical Research	253. Microbial Metabolite Receptor FFA2 Improves Post-Ischaemic Reperfusion Dr Kristen Bubb, Monash University	259. The effect of aprocitentan in patients with very high baseline blood pressure Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia	
14:15-14:30	242. Novel informatics approaches for the regulatory management of UVCB substances Hannah Gerstmyer, The University of Sydney	248. Applying Artificial Intelligence to develop high-affinity antagonists of the relaxin receptor, RXFP1 Prof Ross Bathgate, Florey Institute of Neuroscience and Mental Health	254. Bromodomain extra-terminal inhibitors prevent inflammation-induced stromal cell signalling & cardiac dysfunction A/Prof Simon Foster, Cardiac Drug Discovery Lab, QIMR Berghofer	260. Chronic hypertension in young women – are we adequately preparing for pregnancy? Dr Madeleine Cosgrave, Eastern Health Clinical School, Monash University	
14:30-14:45	243. Isolated compounds from ginseng and green tea increase oxidative stress in spermatozoa Dr Tayler Catherine Kent, Murdoch University	249. Development of P2Y2 receptor antagonists with improved physicochemical properties for drug discovery Dr Natasha Dale, The University of Nottingham	255. Marginal Zone B cells: potential drivers of inflammation associated with hypertension Dr Hericka Bruna Figueiredo Galvao, La Trobe University	261. Australia lacks a high-quality national database system on blood pressure Dr Alexandra Gallagher, The University of Sydney	
14:45-15:00	244. Assessing the impact of Phenazopyridine on the efficacy of BCG-immunotherapy Georgia Bourlotos, Flinders University	250. Structure-Guided Design of Allosteric Modulators at the Delta Opioid Receptor Dr Arisbel Batista Gondin, Monash University	256. Retinal capillary rarefaction is associated with systemic immune-inflammatory index in hypertensive patients Dr Louise Woodhams, Dobney Hypertension Centre	262. Improved cardiovascular disease risk management via pathology services: a randomised clinical trial Prof James Sharman, Menzies Institute for Medical Research	
15:00-15:15	245. Towards Safer Medication Practices: A Retrospective Analysis of Adverse Drug Reactions Jing Xin Goh, The University of Sydney	251. Co-trimoxazole-induced SCAR is globally defined by HLA-B alleles with shared peptide-binding specificities A/Prof Andrew Gibson, Murdoch University	257. Low-dose Australian air pollution promotes neutrophilic, steroid-insensitive, experimental asthma Hudson Taylor-Blair, The University of Technology Sydney	263. What attributes influence antihypertensive prescribing to older adults? A discrete choice experiment Dr Edel O'hagan, Westmead Applied Research Centre, The University of Sydney	
15:15-15:30	246. A novel GPCR heteromer demonstrates unique pharmacology revealed with live cell biosensors Henry Purbrick, The University of Western Australia	252. Implementation of a pharmacogenomic testing service in residential aged care: Preliminary findings Eman Wehbe The University of Sydney	258. Targeting C-C motif chemokine receptor 6 with PF-07054894 in COPD William Dewar, University of Technology Sydney	264. Impact of packaging aids on medication errors: a systematic scoping review Ngoc Tran, The University of Sydney	
15:30 – 16:00	Afternoon tea with exhibitors				Foyer E
15:30 – 16:00	Poster presentations Cardiovascular, Innovation & Industry, Clinical pharmacology, Drug discovery, Pharmacoepidemiology, Pharmacogenomics, Comorbidities, Complications of hypertension, Mechanisms of hypertension, Risk factors				
15:30 – 16:00	Toxicology AGM	Pharmacogenomics AGM	Respiratory & Inflammation AGM	Neuropharmacology AGM	

Bridging the Gap: Assessing Aldosterone Synthase Inhibition in Hypertension Management

Join the workshop Thursday, 11th December, 1:00 PM – 2:00 PM Hall E1
<https://www.astrazeneca.com.au/> AU – 23986 Date: NOV 2026





Comprehensive Biospecimen Solutions

BIOIVT.COM

Room	E1	E2	E3	Hall C Lower Section
16:00 – 18:00	Bellberry New Investigator Award Sponsored by  Bellberry Limited supporting research and ethics			HA student oral finalists 16:00-17:15
Chair	Prof Andrew Rowland, Flinders University Dr Mouna Sawan, The University of Sydney			Prof Francine Marques, Monash University and Dr Dean Picone, The University of Sydney
	265. Psilocybin-assisted psychotherapy: A trans-diagnostic therapy? Dr Jonathan Brett, UNSW/St. Vincent's Hospital 266. Characterising a rat model of polycystic kidney disease to identify therapeutic targets Dr Quynh Dinh, RMIT University 267. Understanding sex-based cardiometabolic responses to contemporary diabetes therapies' Dr Abhipree Sharma, Monash University 268. Novel in vivo and ex vivo applications utilising transgenic TGFβ overexpressing mice Dr Julia Chitty, Monash University			269. Reimagining Hypertension Care: Feasibility and Acceptability of Remote Wearable Blood Pressure Monitoring Heshmiha Christy, UNSW Sydney 270. Hypertensive response to exercise, fitness, left ventricular hypertrophy and cardiovascular outcomes Catalina Silva Ruiz, The University of Tasmania 271. Interleukin-18 signals via a non-canonical short IL-18 pathway during deoxycorticosterone/salt-induced hypertension Buddhila Wickramasinghe, La Trobe University 272. High-fibre diet intervention post-stroke is protective in male but not female mice Charlotte Barker, Monash University 273. Exploring the role of steroid profiling in understanding the pathophysiology of hypertension Dr Sonali Shah, Hudson Institute of Medical Research
17:15-17:45	274. HA Lecture: RD Wright I Body fluids and blood pressure: lost in translation A/Prof Jens Titze, DukeNUS Medical School		Sponsored by 	Hall C Lower Section
17:45-18:15	275. HA Lecture: Paul Korner Awardee Lecture I Hormones and Hypertension; Medicine and Music Prof Michael Stowasser, Frazer Institute, The University of Queensland, Princess Alexandra Hospital			
Chair	Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia			
18:30-20:00	ASCEPT&HA Presidents' Reception			Gilbert Suite
19:00-22:00	Student Dinner			Lady Burra Brewhouse



Supporting better health outcomes

Therapeutic Guidelines recognised as a leading source of accurate, independent, and practical treatment advice for a wide range of clinical conditions.

More than 2,500 topics covering disorders encountered in clinical practice, integrated into a single product for your computer or mobile.

tg.org.au



07:30 – 17:00	Registration desk open			Foyer E
07:00-08:00	HA Round table			Skyway room 1&2
08:00-08:30	300. HA Lecture: Austin Doyle I Functional testing in autoinflammatory diseases Prof Seth Masters, Centre for Innate Immunity and Infectious Disease, Hudson Institute of Medical Research			Hall C Lower Section
08:30-09:00	301. HA Lecture: Colin I Johnston Lecturer I Rewriting blood pressure control through the gut microbiome: A translational odyssey Prof Francine Marques, Monash University	Sponsored by Medtronic		
Chair	Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia			
CONCURRENT SESSION 4				
Room	E1	E2	E3	Hall C Lower Section
09:00 – 10:30	Oral presentations 9: Clinical pharmacology & Tony Smith QUM Prize	Oral presentations 10: Pharmacoepidemiology & Clinical pharmacology trainee	Oral presentations 11: Urogenital and gastrointestinal / Neuropharmacology	Oral presentations 12: Complications and comorbidities of hypertension
Chair	Dr Josh Inglis, Flinders Medical Centre and Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney	Darshna Goordeen, Monash University and Dr George Tan, Monash University	Assist/Prof Iris Lim, Bond University and Dr Celine Valant, Monash Institute of Pharmaceutical Sciences	Dr Hericka Figueiredo Galvao, La Trobe University and A/Prof Antony Vinh, La Trobe University
09:00-09:15	302. Adverse drug withdrawal event identification and adjudication Dr Emily Reeve, Monash University	308. Residential aged care quality use of medicines indicators: a Delphi study Dr Daria Gutteridge, The University of South Australia	314. Reversible inhibition of bladder mucosa contractile activity by dimethylsulfoxide (DMSO) Prof Russ Chess-Williams, Centre for Urology Research, Bond University	320. Clinical decision-making in primary aldosteronism screening, diagnosis and management: A qualitative study Dr Sandra Hakim, Monash University
09:15-09:30	303. Beyond blood: feasibility of saliva-based assays for antiviral therapeutic drug monitoring Cassandra Lai, The University of Sydney	309. Psychotropic use in community-dwelling people with dementia: a systematic review and meta-analysis Edward Chun Yin Lau, Sydney Pharmacy School, The University of Sydney	315. Female mice exhibit reduced hallmarks of MASH in the GAN DIO model Isabella Simon, Monash University	321. Heart failure exacerbates renal hypoxia and acute kidney injury after cardiopulmonary bypass Prof Clive May, Florey Institute of Neuroscience and Mental Health
09:30-09:45	304. Medication data collection in Frailty Intervention Through Specific Therapies (FITTEST) trial participants Temitope Esther Afolabi, The University of Sydney	310. Adverse Outcomes Associated with Risperidone in Dementia: An Individual Participant Data Meta-Analysis Harry Le, The University of Sydney	316. Unravelling the mechanisms underlying BCG induced lower urinary tract side effects Meera Elmasri, Flinders University	322. Sex differences in response to podocyte depletion in aged mice Dr Sarah Walton, Monash University
09:45-10:00	305. Navigating Complexity: Developing a Regulatory Pathway for Advanced Therapeutics in Australia (Tony Smith QUM Prize finalist) Kerry Watts, NSW Ministry of Health	311. Impact of medication management interventions on healthcare utilisation in dementia: Systematic review Jiefei Yu, The University of Sydney	317. Targeting endosomal metabotropic glutamate receptor 5 signalling for the treatment of pain Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences	323. Linking Renal Medullary Hypoxia to Mitochondrial Dysfunction in Septic Acute Kidney Injury Dr Connie Ow, Florey Institute of Neuroscience and Mental Health
10:00-10:15	306. What support Healthcare Professionals need to deprescribe opioids at transitions of care (Tony Smith QUM Prize finalist) Jeffery Wang, The University of Sydney	312. A qualitative evidence synthesis on the unintended consequences of prescription opioid policies Patrick Lu, The University of Sydney	318. Untangling Polypharmacy Molecular Signature Through Network Pharmacology Approaches: Study on Hippocampal Proteomics Kevin Winardi, The University of Sydney & Kolling Institute	324. Beyond diet and obesity: establishing a sympathetic nervous system-driven model of MAFLD Dr Lakshini Herat, Dobney Hypertension Centre, The University of Western Australia
10:15-10:30	307. Patient Decision-Aids for Pain Medication Management: A Scoping Review (Tony Smith QUM Prize finalist) Dr Aili Langford, The University of Sydney	313. Systematic review evaluating efficacy and safety of colchicine in coronary artery disease Dr Deisi Christopher, Flinders Medical Centre	319. Kv1.3 blockade improves cognitive performance in APP/PS1 mice Dr Ryan Keenan, Monash University	325. Megadose sodium ascorbate attenuates splanchnic sympathetic nerve activity in Gram-negative rodent sepsis Dr Rachel Peiris, The Florey Institute of Neuroscience and Mental Health
10:30– 11:00	Morning tea with exhibitors			Foyer E
10:30– 11:00	Poster presentations Toxicology, Urogenital and gastrointestinal, Education, Neuropharmacology, Respiratory and inflammation, Clinical trials and blood pressure measurement, New therapies, Hypertension - Other, Public health and epidemiology			
CONCURRENT SESSION 5				
Room	E1	E2	E3	Hall C Lower Section
11:00 – 13:00	Symposium 5: Consumer and community involvement in hypertension and pharmacology research	Symposium 6: From Trial-and-Error to Precision: Pharmacogenomic-Guided Medication Use in Mental Health Care	Symposium 7: Transforming Lung Cancer: from Discovery to Delivery	Symposium 8 (HA): A Pinch of Salt: New Insights into Blood Pressure Regulation
Chair	Dr Lisa Kouladjian O’Donnell and Dr Mouna Sawan, The University of Sydney	A/Prof Sophie Stocker, The University of Sydney and Dr Sam Mustafa, myDNA Life Australia	Dr Richard Kim, University of Technology Sydney and Mariah Stavrou, UNSW Sydney	A/Prof Anthony Vinh, La Trobe University and Dr Katrina Mirabito Colafella, Monash University
11:00-11:30	326. Meaningful engagement to develop culturally relevant health interventions with Aboriginal and Torres Strait Islander people Dr Andrew Goodman, The Australian e-Health Research Centre, CSIRO	329. Translating pharmacogenomics and precision dosing in major depressive disorder: the ALIGNED study A/Prof Kathy Wu, St Vincent’s Hospital	333. Development of a biologically-selective treatment for lung adenocarcinoma A/Prof Nicola Smith, UNSW Sydney	337. Nitrogen metabolism in salt-sensitive hypertension A/Prof Jens Titze, DukeNUS Medical School
11:30-12:00	327. Creating Opportunities for Consumer Involvement: Reflections of a Discovery Scientist and Research Centre Director Prof Grant Drummond and Dr Vivian Tran, La Trobe University	330. The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind RCT of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care Dr Sibel Saya, The University of Melbourne	334. A novel model of air pollution-induced lung cancer Dr Chantal Donovan, University of Technology Sydney	338. Implementing potassium-enriched salt substitutes in Australia and globally to reduce blood pressure on a population level Prof Alta Schutte, UNSW Sydney and The George Institute for Global Health
12:00-12:30	328. Ingredients for successful partnerships between researchers and consumers John Stevens and Dr Niamh Chapman, The University of Sydney	331. The science of delivering pharmacogenomic test results to guide prescribing in Australia Prof Luke Hesson, Douglass Hanly Moir Pathology	335. TRACKER Biobank: empowering lung cancer breakthroughs Dr Senthuran Shivakumar, University of Melbourne and Austin Health	339. Salty guts: A high salt diet promotes atherosclerosis through a gut-bone marrow axis Prof Andrew Murphy, Baker Heart and Diabetes Institute
12:30-13:00	Panel discussion and Q&A	332. The value proposition: Is pharmacogenomic-guided prescribing of medicines to treat mental health conditions economically sound? Prof Christine Lu, Royal North Shore Hospital, The University of Sdney	336. Sequencing approaches for improving diagnosis – insights from industry Dr Baoming Wang, University of Technology Sydney	340. Sodium & Sensibility: The Gendered Tale of Salt Regulation Dr Zoe McArdle, Monash University

13:00 – 14:00	Lunch with exhibitors			Foyer E
13:00 – 14:00	Poster presentations Toxicology, Urogenital and gastrointestinal, Education, Neuropharmacology, Respiratory and inflammation, Clinical trials and blood pressure measurement, New therapies, Hypertension - Other, Public health and epidemiology			
13:00-14:00	LUNCH WORKSHOP: Bridging the Gap: Innovations and Unmet Needs in Hypertension Care Facilitators: Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia Prof Alta Schutte, UNSW Sydney Prof Michael Stowasser, University of Queensland Frazer Institute, Greenslopes and Princess Alexandra Hospitals		LUNCH WORKSHOP: Bellberry–ASCEPT Partnership on New Approach Methodologies (NAMs) Facilitators: Prof Carl Kirkpatrick, Centre for Medicine use and safety, Monash University Prof Andrew McLachlan AM, Sydney Pharmacy School Leanne Weekes, Bellberry Kylie Sproston, Bellberry	
	Delivered by 		Delivered by  	
Room	E1		E2	
CONCURRENT SESSION 6				
Room	E1	E2	E3	Hall C Lower Section
14:00 – 15:30	ASCEPT Garth McQueen Oral Prize Session			HA ECR oral finalists 14:00-15:00
Chair	Dr Luke Grundy, Flinders University and Dr Chantal Donovan, University of Technology Sydney			Dr Isabella Tan, The George Institute for Global Health and Prof Ross Tsuyuki, University of Alberta
14:00-14:15	341. Therapeutic Potential of Human Amnion Epithelial Cells for Improving Post-Stroke Cognitive Outcomes David Wong Zhang, La Trobe University			347. Effects of prebiotic HAMSAB supplementation on 24-hour ambulatory blood pressure indices Dr Rikeish R Muralitharan, Monash University, Victorian Heart Institute
14:15-14:30	342. FPR2 agonist attenuates pulmonary arterial hypertension and right ventricular dysfunction in mice Ting Fu, Monash Institute of Pharmaceutical Sciences			348. IRAP Inhibition as a Novel Anti-Fibrotic Strategy for Post-MI Heart Failure Dr Yan Wang, Monash University
14:30-14:45	343. IRAP – A novel target in the treatment of Pulmonary Arterial Hypertension Supitchaya (Leena) Watakul, Monash University			349. Low dietary fibre: a sex-dependent regulator of inflammation and blood pressure Dr Joanne O'Donnell, Monash University
14:45-15:00	344. Characterising BB3: a novel therapeutic target in lung adenocarcinoma Mariah Stavrou, UNSW Sydney			350. Ad hoc use of home blood pressure monitoring undermines clinical utility Dr Annika Wilson, The University of Tasmania
15:00-15:15	345. Protection in IRAP deficient mice differs between photothrombotic and MCAO induced stroke Rianna Tadd-Lennox, Monash University			
15:15-15:30	346. Modeling acute silica-induced inflammation using precision-cut lung slices Varuni Premaratne, Monash University			
15:00- 15:30	351. BIHS Lecture I Hypertensive pregnancy: a truly multi-organ disorder...can the postpartum period offers a window to modulate lifetime risks of end organ damage? Dr Jamie Kitt, Oxford & Thames Valley			Hall C Lower Section
Chair	Dr Isabella Tan, The George Institute for Global Health and Prof Ross Tsuyuki, University of Alberta			
15:30 – 16:00	Afternoon tea with exhibitors			Foyer E
15:30 – 16:00	Poster presentations Toxicology, Urogenital and gastrointestinal, Education, Neuropharmacology, Respiratory and inflammation, Clinical trials and blood pressure measurement, New therapies, Hypertension - Other, Public health and epidemiology			
15:30-15:55	Drug Disposition & Response AGM	Pharmacoepidemiology AGM	Cardiovascular AGM	Innovation & Industry AGM
Room	E1	E2	E3	Hall C Lower Section
CONCURRENT SESSION 7				
16:00 – 17:00	352. Keynote presentation: ASCEPT Rand medal I From Organ Baths to Omics: Unravelling Endothelial, Oxidative and Immune Mechanisms in Cardiovascular Disease Prof Grant Drummond, La Trobe University			Hall C Lower Section
Chair	Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney			
Room	E1		E2	
17:00 – 18:00	ASCEPT AGM		HA AGM	
19:00 – 23:30	Meeting Dinner		Sponsored by 	National Wine Centre



Launching new futures

Adelaide University is a new institution built for a changing world.



PRV 14404/CRICOS 04249J

CELEBRATING

Winner Telstra National
Championing Health
#TelstraBestOfBusinessAward

Bb Bellberry Limited

supporting research and ethics

Australia's largest reviewer



Human Research Ethics Committees

Working across all phases of clinical and device trials, and social and behavioural studies, our teams support researchers in private, public, academic and government settings Australia-wide.

In 2024 Bellberry supported

~40%

of CTN clinical
trials in Australia

1,760+ research
organisations

7,080+ investigators
and site staff

11,250+ research
applications



We Care

HRECs Excellence
With two key objectives:
to protect the welfare
of human research
participants, and improve
the quality, efficiency and
effectiveness of research.

Learn more >



We Give

Philanthropic Activities
We support grants for
people, projects and
direct action initiatives.


Learn more >



We Lead

Research, Policy & Advocacy
We are NHMRC certified,
and AAHRPP accredited
for excellence and ethically
sound processes. The first
and only organisation to
achieve this in Australia.

Learn more >



We Innovate

Strategic Projects
Development of new
products & services to
support & improve the
excellence of scientific
& ethical review and the
delivery of research.

Learn more >



For more information about Bellberry and our services >

www.bellberry.com.au

+61 8 8361 3222

bellberry@bellberry.com.au



08:30 – 15:00	Registration desk open Foyer			
Room	E1	E2	E3	
09:00-10:30	Neville Percy Prize flash poster presentations	Robert Whelan Prize flash poster presentations	HA student poster prize presentations	
Chair	A/Prof Nicola Smith, UNSW Sydney and Dr Slade Matthews, The University of Sydney	Dr Luke Grundy, Flinders University and Dr Hericka Figueiredo Galvao, La Trobe University	Dr Lakshini Herat, The University of Western Australia and Dr Ruslan Pustovit, Florey Institute of Neuroscience and Mental Health	
09:00-09:05			400. Deep immunophenotyping reveals associations with human blood pressure Evany Dinakis, Monash University	
09:05-09:10			401. Distinct endothelial cell subtype promotes vascular inflammation and remodelling during aortic stiffening Tayla Gibson Hughes, La Trobe University	
09:10-09:15			402. Microbial metabolite supplementation reduces blood pressure by improving vascular function Phoebe Cheong, Monash University	
09:15-09:20			403. Arterial stiffness shows stronger association with cognitive function in females than males Genevieve Shek, UNSW Sydney	
09:20-09:25			404. Human amnion epithelial cell therapy modulates brain cell heterogeneity in experimental stroke Yeshwanth Reddy Yeraddu, LaTrobe University	
09:25-09:30			405. Gut microbial metabolite acetate and prevention of cardiovascular disease in high-risk women Chaoran Yang, Monash University	
09:30-09:35			406. Neuroinflammation without Hypoxia, and Brain Injury Biomarkers after Cardiopulmonary Bypass in Sheep Dr Taku Furukawa, The Florey, University of Melbourne	
09:35-09:40			407. Team-based hypertension care in Australia: A qualitative study among primary care providers Dr Gautam Satheesh, The University of Sydney	
09:40-09:45	Comfort break			
9:45-10:15			HA ECR poster prize presentations	
Chair			Dr Lindsea Booth, Florey Institute and Prof James Sharman, Menzies Institute for Medical Research	
09:45-09:50			408. Hypertension awareness, treatment and control in Australian young adults Dr Ritu Trivedi, The University of Sydney	
09:50-09:55			409. The impacts of an intracerebrally-administered hydrogel therapeutic-delivery system on the brain post-stroke Dr Adriana Knezic, Monash University	
09:55-10:00			410. Impact of dialysis on cardiovascular, cerebrovascular and renovascular hemodynamics in sepsis Dr Munenori Kusunoki, Florey Institute of Neuroscience and Mental Health	
10:00-10:05			411. Inadequate fibre intake increases gut-derived uremic toxins that contribute to hypertension Dr Chudan Xu, Monash University	
10:05-10:10			412. VEGF inhibitor-induced hypertension is ameliorated by DMSC-EVs in male rats Dr Katrina Mirabito Colafella, Monash University	
10:10-10:15				
10:30 – 11:00	Morning tea with exhibitors		Foyer E	
CONCURRENT SESSION 8				
Room	E1	E2	E3	Hall C Lower Section
11:00 – 13:00	Symposium 9: Recent applications of physiologically-based pharmacokinetics (PB-PK) in drug discovery and development	Symposium 10: The changing landscape of drug development and early phase Clinical Trials	Symposium 11: Spatial omics in drug discovery research	Symposium 12 (HA): Improving the Cardiometabolic Health of People with Intellectual Disability
Chair	A/Prof Dave Shackleford, Cornelia Landersdorfer and Prof Carl Kirkpatrick, Monash University	Dr Angela Molga, Central Adelaide Local Health Network	Dr Hericka Bruna Figueiredo Galvao, La Trobe University and Dr Simon Foster, QIMR Berghofer	Prof Gavin Lambert, Swinburne University of Technology and Dr Rachel Mcdonald, Medtechvic & Swinburne University of Technology
11:00-11:30	413. Breathing Life into Physiologically Based Pharmacokinetics (PBPk): Modeling Inhaled Oxytocin for Postpartum Care Prof Carl Kirkpatrick, Monash University	417. Unique translational clinical pharmacology challenges with novel, non-traditional drug molecules: the example of siRNA therapeutics Dr Tom Polasek, Monash University	421. Vascular Smooth Muscle Cell Heterogeneity: New Insights into Coronary Artery Atherosclerosis Dr Maria Jelinic, La Trobe University	425. Improving Cardiometabolic disease outcomes for people with intellectual disability Prof Julian Trollor, Disability Health, University of New South Wales
11:30-12:00	414. Enhancing Physiologically Based Pharmacokinetic Models with Lymphatic Flow to Predict mRNA-LNP Biodistribution in Rats Dr Jessica Tait, Monash University	418. The challenges of conducting psychedelic clinical trials Dr Jonathan Brett, UNSW Sydney and St. Vincent’s Hospital	422. Machine learning and spatial multiomics to study drug targets and responses A/Prof Quan Nguyen, QIMR Berghofer	426. Understanding the mechanisms of cardiac and metabolic risk in individuals with intellectual disability A/Prof Elisabeth Lambert, Swinburne University of Technology
12:00-12:30	415. What lies beneath - PBPk modelling to support subcutaneous administration of Anakinra in preterm neonates Jia Li, Monash University	419. Challenges of conducting trials with Complement inhibitors Dr Millie Wang, New Zealand Clinical Research	423. Using spatial proteomics on human cardiac organoids to map cardiac cell-cell and cell-matrix interactions in fibrosis Dr Lynn Devilee. QIMR Berghofer	427. Using co-design to improve health outcomes in disadvantaged communities Prof Rachael McDonald, The MedTechVic hub, Swinburne University of Technology

12:30-13:00	416. In Vitro Models Integrating Metabolism and Transport to Support Mechanistic PK Modeling in Early Drug Discovery Dr Kenneth Brouwer, PhD, RPH, BioVIT	420. Technical aspects of modern early phase study design – what does the future of early phase clinical studies look like? Prof Sepehr Shakib, The University of Adelaide	424. End-to-end spatial transcriptomics analysis with VR-Omics Prof Mirana Ramialison, Murdoch Children’s Research Institute	428. Designing and implementing the Food and Lifestyle Information Program (FLIP) culinary nutrition intervention for adults with intellectual disability Dr Roberta Asher, The University of Newcastle
13:00-13:45	Lunch with exhibitors			Foyer E
13:45-14:45	429. Closing Keynote address It’s what they do that counts: activity-based assays as a new approach in clinical and forensic toxicology A/Prof Christophe Stove, Ghent University		Sponsored by 	Hall C Lower Section
Chair	Prof Nick Buckley, The University of Sydney			
14:45-15:45	Awards and meeting close			

WORLD-CLASS PHARMACY AND PHARMACEUTICAL SCIENCE RESEARCH

The Monash Institute of Pharmaceutical Sciences (MIPS) is a dynamic, innovative and ambitious centre of research and learning, with a growing emphasis on cutting edge global projects. More than 450 MIPS scientists research drug discovery, design, delivery and use. Our therapeutic strengths lie in neuroscience and mental health, cardiovascular and metabolic health, and global health.

Find out more: monash.edu/mips



MONASH

University

MONASH

INSTITUTE OF PHARMACEUTICAL SCIENCES




Trusted information for confident decision making

- ✓ Independent and evidence-based
- ✓ Concise for point of care use
- ✓ Unique comparative insights
- ✓ Supports the Quality Use of Medicines

For more information visit amh.net.au

OMRON

BLOOD PRESSURE MONITORS

#1 share No.1 **400million** units sold*

Global Leaders in Home Blood Pressure Monitoring

HEM-907

Built with precision through Japanese engineering, the OMRON HEM-907 Professional Blood Pressure Monitor is designed to deliver the accuracy and reliability medical professionals demand.

Used by clinicians worldwide, OMRON's practitioner-grade monitors provide consistent, reproducible readings to support confident patient assessment and care decisions.

As a global leader in blood pressure technology, OMRON Healthcare continues to set the standard for innovation and quality in clinical measurement.

Global Home Appliance Market Comprehensive Survey 2025, Fuji Keizai Co., Ltd. (forecast for 2024)

* Global cumulative sales of home electronic blood pressure monitors (as of September 2025)